Abstract:BACKGROUND:Accurate diagnosis of major depressive disorder (MDD) remains difficult, and one of the key challenges in diagnosing MDD is the lack of reliable diagnostic biomarkers. The objective of this study was to explore gene networks and identify potential biomarkers for MDD.METHODS:In the present study, we performed a comprehensive analysis of the mRNA expression profiles using blood samples of four patients with MDD and four controls by RNA sequencing. Differentially expressed genes (DEGs) were screened, and functional and pathway enrichment analyses were performed using the Database for Annotation, Visualization, and Integrated Discovery. All DEGs were inputted to the STRING database to build a PPI network, and the top 10 hub genes were screened using the cytoHubba plugin of the Cytoscape software. The relative expression of 10 key genes was identified by quantitative real-time polymerase chain reaction (qRT-PCR) of blood samples from 50 MDD patients and 50 controls. Plasma levels of SQSTM1 and TNFα were measured using an enzyme-linked immunosorbent assay in blood samples of 44 MDD patients and 44 controls. A sucrose preference test was used to evaluate depression-like behavior in chronic unpredictable mild stress (CUMS) model rats. Immunofluorescence assay and western blotting were performed to study the expression of proteins in the brain samples of CUMS model rats.RESULTS:We identified 247 DEGs that were closely associated with MDD. Gene ontology analyses suggested that the DEGs were mainly enriched in negative regulation of transcription by RNA polymerase II promoter, cytoplasm, and protein binding. Moreover, Kyoto Encyclopedia of Genes and Genomes pathway analysis suggested that the DEGs were significantly enriched in the MAPK signaling pathway. Ten hub genes were screened through the PPI network, and qRT-PCR assay revealed that one and six genes were downregulated and upregulated, respectively; however, SMARCA2, PPP3CB, and RAB5C were not detected. Pathway enrichment analysis for the 10 genes showed that the mTOR signaling pathway was also enriched. A strong positive correlation was observed between SQSTM1 and TNFα protein levels in patients with MDD. LC3 II and SQSTM1 protein levels were increased in the CUMS rat model; however, p-mTOR protein levels were decreased. The sucrose preference values decreased in the CUMS rat model.CONCLUSIONS:We identified 247 DEGs and constructed an MDD-specific network; thereafter, 10 hub genes were selected for further analysis. Our results provide novel insights into the pathogenesis of MDD. Moreover, SQSTM1, which is related to autophagy and inflammatory reactions, may play a key role in MDD. SQSTM1 may be used as a promising therapeutic target in MDD; additionally, more molecular mechanisms have been suggested that should be focused on in future in vivo and in vitro studies.

Reduced ENA78 Levels As Novel Biomarker for Major Depressive Disorder and Venlafaxine Efficiency: Result from a Prospective Longitudinal Study

Association of Anhedonia with Brain-Derived Neurotrophic Factor and Interleukin-10 in Major Depressive Disorder

Increased Plasma Levels of IL-6 Are Associated with Striatal Structural Atrophy in Major Depressive Disorder Patients with Anhedonia

Venlafaxine Inhibits the Upregulation of Plasma Tumor Necrosis Factor-Alpha (Tnf-Α) in the Chinese Patients with Major Depressive Disorder: A Prospective Longitudinal Study

CYP1A2 Genetic Polymorphism is Associated with Treatment Remission to Antidepressant Venlafaxine in Han Chinese Population

Microarray Analysis of the Major Depressive Disorder Mrna Profile Data.

Association of APC and REEP5 Gene Polymorphisms with Major Depression Disorder and Treatment Response to Antidepressants in a Han Chinese Population

Peripheral Blood Mononuclear Cell Biomarkers for Major Depressive Disorder: A Transcriptomic Approach

A Preliminary Investigation on Plasma Cell Adhesion Molecules Levels by Protein Microarray Technology in Major Depressive Disorder

LRFN5 and OLFM4 as novel potential biomarkers for major depressive disorder: a pilot study

Identification of Potential Biomarkers for Major Depressive Disorder: Based on Integrated Bioinformatics and Clinical Validation

An Analysis of Plasma Reveals Proteins in the Acute Phase Response Pathway to Be Candidate Diagnostic Biomarkers for Depression

Differentially expressed genes related to major depressive disorder and antidepressant response: genome-wide gene expression analysis

Identification of Key Genes and Crucial Pathways for Major Depressive Disorder Using Peripheral Blood Samples and Chronic Unpredictable Mild Stress Rat Models

Decreased Plasma Neuroactive Amino Acids and Increased Nitric Oxide Levels in Melancholic Major Depressive Disorder.

GRIK4 and GRM7 gene may be potential indicator of venlafaxine treatment reponses in Chinese of Han ethnicity.

A Study of the Functional Significance of Epidermal Growth Factor in Major Depressive Disorder

The role of circulating blood microRNA-374 and microRNA-10 levels in the pathogenesis and therapeutic mechanisms of major depressive disorder

In vivo evidence of increased vascular endothelial growth factor in patients with major depressive disorder

miR-204-5p plays a critical role in the pathogenesis of depression and anti-depression action of Venlafaxine in the hippocampus of mice

Gene Expression Signatures Differentiating Major Depressive Disorder from Subsyndromal Symptomatic Depression.